Cagnacci Angelo, Villa Paola, Grassi Giuseppina Paola, Biglia Nicoletta, Gambacciani Marco, Di Carlo Costantino, Nocera Francesca, Caruso Salvatore, Becorpi Angelamaria, Lello Stefano, Paoletti Anna Maria
Teaching Unit of Obstetrics and Gynecology, DINOGMI San Martino Hospital of Genova, Genova, Italy.
Department of Women's and Child Health and Public Health Science, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Climacteric. 2025 Feb;28(1):4-14. doi: 10.1080/13697137.2024.2418503. Epub 2024 Nov 6.
The specific Italian Group of Study of the Menopause formulated a consensus opinion on the use of estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) after breast and gynecological cancers. This consensus is based on the risk of recurrence of the specific cancer during ET/HT, the presence of steroid receptors in cancer cells, the use of adjuvant hormone therapies and data on the use of ET/HT after cancer. The following positions were reached. ET/HT can be used after vulvar cancers and melanoma, but with great caution after the rare adenocarcinomas. ET/HT can be used after cervical cancer, but ET should be used with caution after adenocarcinomas. ET/HT can be used after International Federation of Obstetrics and Gynecology (FIGO) stage I-II estrogen-dependent endometrial cancers, except in Black women, and can probably be used after estrogen-independent endometrial cancers. ET/HT cannot be administered or should be used with great caution after most uterine sarcomas. ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.
意大利更年期研究特别小组就乳腺癌和妇科癌症后雌激素治疗（ET）或雌孕激素联合激素治疗（HT）的使用制定了共识意见。该共识基于ET/HT期间特定癌症复发的风险、癌细胞中类固醇受体的存在、辅助激素治疗的使用以及癌症后ET/HT使用的数据。达成了以下立场。ET/HT可在外阴癌和黑色素瘤后使用，但在罕见的腺癌后应极为谨慎。ET/HT可在宫颈癌后使用，但腺癌后使用ET应谨慎。ET/HT可在国际妇产科联合会（FIGO）I-II期雌激素依赖性子宫内膜癌后使用，但黑人女性除外，在雌激素非依赖性子宫内膜癌后可能也可使用。大多数子宫肉瘤后不能使用ET/HT或应极为谨慎地使用。ET/HT可能可在卵巢肿瘤后使用，但颗粒细胞瘤除外，在低级别浆液性卵巢癌和浆液性交界性卵巢肿瘤后应极为谨慎。雌激素受体（ER）/孕激素受体（PR）阳性乳腺癌后的女性使用ET/HT应极为谨慎，ER/PR阴性乳腺癌后可能允许使用。
